Arlene Helen Sharpe (born in 1953) is an American immunologist and Kolokotrones University Professor at Harvard University and Chair of the Department of Immunology at Harvard Medical School. In 2017, she received the Warren Alpert Foundation Prize with Gordon J. Freeman, Lieping Chen, James P. Allison and Tasuku Honjo for their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.[1][2] She served as the hundredth president of the American Association of Immunologists from 2016 to 2017 and served as an AAI Council member from 2013 to 2016.[3] She is the co-director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital.

Arlene H. Sharpe
Born1953
NationalityAmerican
Alma materHarvard College, Harvard Medical School
Known forimmune checkpoint blockade
Scientific career
FieldsImmunology
InstitutionsHarvard Medical School

She graduated from Harvard College and Harvard Medical School.[4]

Awards and honours

edit

References

edit
  1. ^ "2017 Recipient, Arlene Sharpe, Harvard Medical School". www.warrenalpert.org. Archived from the original on 8 October 2017. Retrieved 8 October 2017.
  2. ^ "Warren Alpert Foundation Prize Recipients 2017". www.warrenalpert.org. Retrieved 8 October 2017.
  3. ^ a b "Arlene H. Sharpe, M.D., Ph.D." www.aai.org. Retrieved 8 October 2017.
  4. ^ "Arlene Sharpe". Harvard University. Retrieved 2 August 2018.
  5. ^ "Arlene H. Sharpe". Arnold and Mabel Beckman Foundation. Archived from the original on 2 August 2018. Retrieved 1 August 2018.
edit